Tamización primaria con prueba ADN-VPH en mujeres menores de 30 años: evaluación de tecnología sanitaria / Primary HPV-DNA screening in women under 30 years of age: health technology assessment

Antecedentes A partir del 2014 en Colombia se incorporó la Tamización primaria con prueba de Virus del Papiloma Humano (VPH) desde los 30 hasta los 65 años, cuando la prueba es positiva se hace triage con citología para remisión a colposcopia. Actualmente se discute la conveniencia de iniciar la tamización con prueba de ADN de VPH a partir de los 25 años. De esta manera, el objetivo de esta evaluación de tecnologías sanitarias es analizar la evidencia disponible en torno a la seguridad, efectividad, costoefectividad, valores y preferencias, dilemas éticos y aspectos relacionados con la implementación para el contexto colombiano de la prueba ADN-VPH como estrategia de tamización cervical en mujeres menores de 30 años. Dominios a evaluar Eficacia clínica y seguridad 1. Tasa acumulada de neoplasia intraepitelial cervical (NIC) grado 2 o más avanzado luego de 2 rondas de tamización. 2. Tasas acumuladas de cáncer invasor de cérvix luego de 2 rondas de tamización. 3. Seguridad: remisión a colposcopia. Costo-efectividad Costo efectividad para Colombia. Otros dominios considerados Aspectos éticos asociados a la tamización cervical en mujeres menores de 30 años. Aspectos organizacionales y del individuo. Barreras y facilitadores relacionados con la implementación en el contexto colombiano de la tamización cervical en mujeres menores de 30 años. Métodos Evaluación de efectividad y seguridad clínicas Se realizó una búsqueda sistemática de la literatura en MEDLINE, Embase y CENTRAL de revisiones sistemáticas y ensayos clínicos. Se calificó el cuerpo de la evidencia con la aproximación GRADE. Posteriormente, se convocó a un grupo interdisciplinario a una mesa de trabajo en donde se presentó la evidencia recuperada, dando paso a la discusión y a la construcción de las conclusiones, siguiendo los lineamientos de un consenso formal acorde a la metodología RAND/UCLA. Estudio económico Se hizo una búsqueda sistemática de la literatura de estudios que hubieran evaluado el costo-efectividad para Colombia. Resultados De 7.659 referencias recuperadas se incluyeron 8 estudios. Resultados clínicos Se realizó un análisis integrativo de 5 ensayos clínicos aleatorizados que cumplieron con los citerios de inclusión. Cuando se compara frente a la citología, la tamización primaria con ADN-VPH en mujeres menores de 30 años, podría asociarse con una mayor frecuencia de detección de lesiones NIC2+ durante la primera ronda de cribado (RR: 1.57; IC: 1,20 a 2,04; certeza en la evidencia baja), con una menor incidencia de NIC2+ (RR:0,67; IC: 0,48 a 0,92; certeza en la evidencia baja) y se asocia con una menor frecuencia de carcinoma invasor al término del seguimiento (RR: 0,19; IC: 0,07 a 0,53; certeza en la evidencia alta). Resultados económicos Desde el punto de vista económico, la alternativa de ADN-VPH y triage con citología desde los 25 años quizás representa la alternativa más costo-efectiva para Colombia (razón costo-efectividad incremental $8.820.980 COP año 2013). Otras implicaciones Dos estudios sugieren que las barreras de implementación, atribuibles a circunstancias de intermediación, de orden público y de carácter geográfico, podrían ser solventadas por nuevas tecnologías o estrategias de cribado. Es importante considerar alternativas de forma de administración y de prestación de servicios para solventar algunas barreras de aceptabilidad y acceso. Todo programa de tamización cervical debe contemplar los principios éticos de no maleficencia, beneficencia, autonomía y equidad. Futuros estudios deben enfocarse en analizar nuevas tecnologías de cribado con énfasis en población menor de 30 años. Conclusiones El uso de la prueba ADN-VPH como estrategia de tamización en mujeres menores de 30 años es una intervención probablemente efectiva y costoefectiva para Colombia. Futuros estudios deben enfocarse en analizar nuevas tecnologías de cribado con énfasis en población menor de 30 años.

Background Primary screening with Human Papilloma Virus (HPV) testing was introduced in Colombia in 2014 for individuals between 30 and 65 years of age. When the result is positive, cytology triage is performed for colposcopy referral. The convenience of initiating HPV-DNA testing for screening at 25 years of age is currently a subject of discussion. Therefore, the objective of this health technology assessment (HTA) is to analyze the available evidence regarding safety, efficacy, cost-effectiveness, values and preferences, ethical dilemmas and considerations pertaining to the implementation of the HPV-DNA test as a cervical screening strategy in women under 30 years of age in the Colombian context. Domains to be assessed Clinical efficacy and safety 1. Cumulative rate of cervical intraepithelial neoplasia (CIN) grade 2 or high-er after 2 screening rounds. 2. Cumulative rates of invasive cancer of the uterine cervix after 2 screening rounds. 3. Safety: referral to colposcopy Cost-effectiveness Cost-effectiveness for Colombia. Other domains considered Ethical considerations associated with cervical screening in women under 30 years of age. Organizational and individual considerations. Barriers and facilitators pertaining to the implementation of cervical screening in women under 30 years of age in the Colombian context. Methods Clinical efficacy and safety assessment A systematic literature search of systematic reviews and clinical trials was conducted in MEDLINE, Embase and CENTRAL. The body of evidence was rated using the GRADE approach. An interdisciplinary team was then convened to create a working group to review the retrieved evidence. This led to the discussion and construction of the conclusions following the guidelines of a formal consensus in accordance with the RAND/UCLA methodology. Economic study Systematic literature research of studies that had assessed cost-effectiveness for Colombia. Results Out of the 7,659 references retrieved, 8 studies were included. Clinical outcomes An integrative analysis of 5 randomized clinical trials that met the inclusion critera was performed. Compared with cytology, primary HPV-DNA testing in women under 30 years of age could be associated with a lower frequency of CIN+2 lesions during the first screening round (RR: 1.57; CI: 1.20 to 2.04; low evidence certainty), and a lower incidence of CIN+2 (RR: 0.67; CI: 0.48 to 0.92; low evidence certainty). Moreover, it is associated with a lower frequency of invasive carcinoma at the end of follow-up (RR: 0.19; CI: 0.07 to 0.53; high evidence certainty). Economic results From the financial point of view, the use of HPVDNA testing plus cytology-based triage starting at 25 years of age is perhaps the most cost-effective option for Colombia (incremental cost-effectiveness ratio, COP 8,820,980 in 2013). Other implications Two studies suggest that barriers to implementation attributable to intermediation, public unrest and geographic considerations could be overcome with the use of new screening technologies or strategies. It is important to consider administration and service provision alternatives in order to overcome some acceptability and access barriers. Any cervical screening program must take into consideration ethical principles of nonmaleficence, beneficence, autonomy and equity. Future studies should focus on analyzing new screening techniques with emphasis on the population under 30 years of age. Conclusions The use of HPV-DNA testing as a screening strategy in women under 30 years of age is a potentially efficacious and cost-effective intervention for Colombia. Future studies should focus on analyzing new screening technologies, with emphasis on the population under 30 years of age.

Total body mapping in the follow-up of melanocytic lesions: recommendations of the Brazilian Society of Dermatology

Abstract Total body mapping comprises photographic documentation of the entire body surface followed by digital dermatoscopy of selected melanocytic lesions, aiming to compare their evolution over time and identify new lesions. As this is an exam based on comparative analysis of serial dermoscopic body images, standardization of the technique for performing total body mapping is essential. Prepared by specialists from the Brazilian Society of Dermatology, using the modified Delphi method, this article provides recommendations for carrying out total body mapping in Brazil, regarding its indications, technical aspects, and the issuing of the report.

Análisis de los métodos de detección de lesiones orales potencialmente malignas. Revisión sistemática tipo paraguas / Analysis of the detection methods for potentially malignant oral lesions. An umbrella systematic review

Resumen Propósito: determinar la efectividad de detección de lesiones orales potencialmente malignas de cuatro métodos por medio de revisión sistemática tipo paraguas. Fuente de los datos: la búsqueda fue realizada con bases de datos Pubmed y EBSCOhost. Restricción de los años 2013-2018. Estrategia de búsqueda: (early detection of cáncer) AND (mouth neoplasms), (early detection of cáncer) AND (diagnostic techniques and procedures), (mouth neoplasms) AND (diagnostic techniques and procedures). Selección de los estudios: fueron seleccionadas a través de lectura crítica y la lista de chequeo del formato PRISMA, aquellas revisiones sistemáticas cuyo objetivo sea evaluar la efectividad de al menos uno de los métodos de detección de lesiones orales potencialmente malignas, seis estudios cumplieron con los criterios de inclusión. Extracción de datos: mediante la realización de lectura crítica de las revisiones sistemáticas seleccionadas previamente. Resultado de síntesis de los datos: se determina la efectividad a través de la comparación de las medias de porcentajes de sensibilidad y especificidad. Las medias de sensibilidad y especificidad de Vizilite fueron de 81.31 y 25.4%, de Microlux DL de 82.63 y 69.52%, de azul de toluidina de 82.07 y 66.27% y de citología exfoliativa de 76.77 y 80.87%, respectivamente. Conclusiones: los métodos de detección de lesiones orales premalignas evaluados en el presente estudio requieren mayor respaldo de evidencia científica para validar su efectividad. El método con mayor eficacia es el Microlux/DL, debido a sus altos niveles de sensibilidad y especificidad.

Abstract Objective: to determine the effectiveness of four methods for detecting potentially malignant oral lesions through an umbrella systematic review. Source of data: the search was performed in the PubMed and EBSCOhost databases. Years of search limited to 2013-2018. Search strategy: (early detection of cancer) AND (mouth neoplasms), (early detection of cancer) AND (diagnostic techniques and procedures), (mouth neoplasms) AND (diagnostic techniques and procedures). Study selection: using critical reading and the PRISMA checklist, systematic reviews with the objective of evaluating the effectiveness of at least one of the detection methods for potentially malignant oral lesions were selected; six studies met the inclusion criteria. Data extraction: through critical reading of the previously selected systematic reviews. Results of data synthesis: effectiveness was determined by comparing the mean percentages of sensitivity and specificity. Vizilite's sensitivity and specificity means were 81.31 and 25.4%, Microlux DL's were 82.63 and 69.52%, toluidine blue's were 82.07 and 66.27%, and exfoliative cytology's were 76.77 and 80.87%, respectively. Conclusions: the detection methods for pre-malignant oral lesions evaluated in this study need greater scientific evidence to validate their effectiveness. The method with the greatest effectiveness is Microlux/DL, due to its high levels of sensitivity and specificity.

Evaluation of breast cancer in women under 50 in a Mastology service in the Federal District, Brazil

Introduction: Breast cancer is a relevant public health issue, and its incidence has increased in patients aged less than 50 years. This population usually receives a late diagnosis, which contributes with the poor prognosis of the condition. Objective: To assess the percentage of patients diagnosed with breast cancer before the age of 50 and compare them with the group that was diagnosed after the age of 50. Results: The general mean age was 54 years; 75.68% of the patients were younger than 50 years, aged between 40 and 49 years. Among the ones who were younger than 50, 35.14% were in stage T4; 55.41% underwent neoadjuvant chemotherapy; 16.22% presented distant metastasis; and 10.81%, locoregional metastasis. On the other hand, among those aged more than 50, 22.71% were in stage T4; 30.68% underwent neoadjuvant chemotherapy; 11.36% presented distant metastasis; and 6.82%, locoregional metastasis. Conclusion: Breast cancer in women aged less than 50 years in a Mastology service in the Federal District has been a matter of concern, for presenting more advanced tumors at the time of diagnosis; screening is still debatable.

Research Progress on Electrochemical Biosensors for Breast Cancer Detection Based on Nanomaterials / 中国医疗器械杂志

Breast cancer is one of the most serious diseases threatening women's life and health in the world, and the mortality rate is the second in the world. With the progress of nanotechnology and the advantages of nanomaterials in the field of electrochemistry and biosensor, various nanomaterials have been applied in electrochemical biosensors. This makes the electrochemical nano-biosensor in the field of rapid detection of breast cancer has been widely concerned and studied. This paper introduces the important components of electrochemical nano-biosensor for breast cancer detection and the research progress of each component in breast cancer detection, as well as the performance of electrochemical nano biosensor in breast cancer detection and the prospect of its application.

Colon Cancer Detection Methods – A Review

Aim: Colon is one of the major constituent of the large intestine; occurrence of cancer in it is one of the burning issues that remain unresolved. A large number of people get died every year in this problem. Study Design: In the field of medical image processing the detection of Colon cancer is a big challenge. So far, many research works are proposed, however, no research and investigations are found to bring up the best technique to assess the disease. Place and Duration of Study: Several strategies, in view of the spatial analysis of colon biopsy images, and serum and gene analysis of colon samples, have been proposed in such manner. Methods: Quick advancement of colon cancer detection methods, are yet to be analyzed by the help of this particular work which ensures to coming up with best strategies. Results: In this review, we arrange the procedures on the premise of the adopted system and basic data set, and give a detailed description of methods in every category. Also, this study gives a far extensive examination of different colon cancer detection categories, and of multiple procedures inside every category. Conclusions: Further, the majority of the procedures have been assessed on comparative data set to give a reasonable performance correlation. Ultimately this review can helpful for the researches to proceed their research in the field of colon cancer detection.

Transperineal biopsy under ultrasound guidance for prostate cancer detection as an initial and as a repeat biopsy strategy

OBJECTIVE: To present the authors' experience on transperineal prostate sector biopsy (TPSB) in detecting prostate cancer, in identifying both low Gleason prostate cancers as well as clinically significant prostate cancer (Gleason 7 and higher), and in determining anatomical distributions of prostate cancer in both initial and repeat biopsy settings.METHODS: All patients from June 2014 to September 2016 who underwent TPSB, as initial biopsy or repeat biopsy after previous negative transrectal ultrasound-guided biopsy (TRUSPNB) were included. Data for each patient were collected prospectively and subjected to statistical analysis. T test was used for continuous variables while Chi square test or Fisher exact test was used for categorical variables. Multiple logistic regression models were used to identify factors predictive of a positive result.RESULTS: A total 130 patients were included in the study, 73 had TPSB as initial biopsy and 57 as repeat biopsy after previous negative TRUSPNB. The mean patient age of the Initial Biopsy Group (IBG) was 66 years while the mean age for the Repeat Biopsy Group (RBG) was 68 years. The IBG had a lower mean serum PSA level (9.07 ng/mL for IBG and 9.59ng/mL for RBG) and smaller prostate volumes (42.9 mL for the IBG and 44.3mL for the RBG). Prostate cancer was detected in 65.8% (48/73) of the IBG and 40.4% (23/57) of RBG, of which 77.1% (37/48) and 73.9% (17/23) respectively, were clinically significant, defined as a Gleason score of ?7. Of the cancers detected in IBG, 29.2% (14/48) exclusively involved the anterior sector (based on the Ginsburg Study Group's biopsy map), while 30.4% (7/23) were conned exclusively within the anterior sector for the RBG. Increasing PSA level and lower prostate volumes were predictive of cancer detection in RBG, while only increasing PSA level was predictive of a positive result in IBG.CONCLUSION: Transperineal prostate sector biopsy demonstrated a high prostate cancer detection rate for both the initial and repeat biopsy settings. Likewise it provides for excellent sampling of the anterior region of the prostate, as it affords a more accurate sampling of the prostate gland based on a preplanned map and template to sample areas of interests. Similarly, it detects a high proportion of patients with clinically significant prostate cancer. This technique should therefore be highly considered as a first line option for all patients in whom a prostate biopsy is warranted.

Transperineal biopsy under ultrasound guidance for prostate cancer detection as an initial and as a repeat biopsy strategy

@#<p style="text-align: justify;"><strong>OBJECTIVE:</strong> To present the authors' experience on transperineal prostate sector biopsy (TPSB) in detecting prostate cancer, in identifying both low Gleason prostate cancers as well as clinically significant prostate cancer (Gleason 7 and higher), and in determining anatomical distributions of prostate cancer in both initial and repeat biopsy settings.<br /><strong>METHODS:</strong> All patients from June 2014 to September 2016 who underwent TPSB, as initial biopsy or repeat biopsy after previous negative transrectal ultrasound-guided biopsy (TRUSPNB) were included. Data for each patient were collected prospectively and subjected to statistical analysis. T test was used for continuous variables while Chi square test or Fisher exact test was used for categorical variables. Multiple logistic regression models were used to identify factors predictive of a positive result.<br /><strong>RESULTS:</strong> A total 130 patients were included in the study, 73 had TPSB as initial biopsy and 57 as repeat biopsy after previous negative TRUSPNB. The mean patient age of the Initial Biopsy Group (IBG) was 66 years while the mean age for the Repeat Biopsy Group (RBG) was 68 years. The IBG had a lower mean serum PSA level (9.07 ng/mL for IBG and 9.59ng/mL for RBG) and smaller prostate volumes (42.9 mL for the IBG and 44.3mL for the RBG). Prostate cancer was detected in 65.8% (48/73) of the IBG and 40.4% (23/57) of RBG, of which 77.1% (37/48) and 73.9% (17/23) respectively, were clinically significant, defined as a Gleason score of ?7. Of the cancers detected in IBG, 29.2% (14/48) exclusively involved the anterior sector (based on the Ginsburg Study Group's biopsy map), while 30.4% (7/23) were conned exclusively within the anterior sector for the RBG. Increasing PSA level and lower prostate volumes were predictive of cancer detection in RBG, while only increasing PSA level was predictive of a positive result in IBG.<br /><strong>CONCLUSION: </strong>Transperineal prostate sector biopsy demonstrated a high prostate cancer detection rate for both the initial and repeat biopsy settings. Likewise it provides for excellent sampling of the anterior region of the prostate, as it affords a more accurate sampling of the prostate gland based on a preplanned map and template to sample areas of interests. Similarly, it detects a high proportion of patients with clinically significant prostate cancer. This technique should therefore be highly considered as a first line option for all patients in whom a prostate biopsy is warranted.</p>

Analysis of Participant Factors That Affect the Diagnostic Performance of Screening Mammography: A Report of the Alliance for Breast Cancer Screening in Korea

OBJECTIVE: To analyze participant factors that affect the diagnostic performance of screening mammography. MATERIALS AND METHODS: We enrolled 128756 cases from 10 hospitals between 2005 and 2010. We analyzed recall rate, cancer detection rate (CDR) per 1000 examinations, positive predictive value (PPV), sensitivity, specificity, false positive rate (FPR), and interval cancer rate (ICR) per 1000 negative examinations according to participant factors including age, breast density, and number of visit to the same institution, and adjusted for confounding variables. RESULTS: Increasing age improved recall rates (27.4% in 40's, 17.5% in 50's, 11.1% in 60's, and 8.6% in 70's), CDR (2.7, 3.2, 2.0, and 2.4), PPV (1.0, 1.8, 1.8, and 2.8%), sensitivity (81.3, 88.8, 90.3, and 94.7%), specificity (72.7, 82.7, 89.0, and 91.7%), and FPR (27.3, 17.3, 11.0, and 8.4%) (p < 0.05). Higher breast density impaired recall rates (4.0% in P1, 9.0% in P2, 28.9% in P3, and 27.8% in P4), PPV (3.3, 2.3, 1.2, and 1.3%), specificity (96.1, 91.2, 71.4, and 72.5%), and FPR (3.9, 8.9, 28.6, and 27.6%) (p < 0.001). It also increased CDR (1.3, 2.1, 3.3, and 3.6) and ICR (0.2, 0.3, 0.6, and 1.6) (p < 0.05). Successive visits to the same institution improved recall rates (20.9% for one visit, 10.7% for two visits, 7.7% for more than three visits), PPV (1.6, 2.8, and 2.7%), specificity (79.4, 89.6, and 92.5%), and FPR (20.6, 10.4, and 7.5%) (p < 0.001). CONCLUSION: Young age and dense breasts negatively affected diagnostic performance in mammography screening, whereas successive visits to the same institution had a positive effect. Examinee education for successive visits to the same institution would improve the diagnostic performance.

Retinoblastoma in Mexico: part I. A review of general knowledge of the disease, diagnosis, and management / Retinoblastoma en México: parte I. Revisión del conocimiento general de la enfermedad, diagnóstico y tratamiento

AbstractThis is the first of a two-part review that aims to report the current knowledge of retinoblastoma (Rb) and its implications in Mexico (including the authors' experience at the leading Rb centers), identify the gaps in practice, and propose solutions to improve diagnosis, treatment, and patient uptake. In this first part, general knowledge of Rb diagnosis and management is summarized with a focus on the latest advances in chemotherapy. A general review of peer-reviewed literature of Rb was conducted on PubMed. Key findings were summarized.Provided there is early detection and referral of patients followed by appropriate conservative management, Rb is curable. In developed countries, the primary treatment outcome is ocular salvage with sight preservation. Advanced chemotherapeutic options such as intra-arterial and intravitreal chemotherapy can now save even the most advanced tumors.Advances in Rb therapy are generally limited to developed countries. The implications in Mexico, of the findings from this review will be discussed in Part 2, which will be a comprehensive situational analysis of the state of Rb programming in Mexico, including a review of current demographic data available from hospitals that have Rb programs or treat Rb.

ResumenEsta es la primera parte de un trabajo de revisión donde se reportan los conocimientos actuales del retinoblastoma (Rb) y sus implicaciones en México (incluyendo la experiencia de los autores en los principales centros de referencia), así como las brechas en la práctica y las posibles soluciones para mejorar el diagnóstico, tratamiento y referencia de pacientes. En esta parte se resumen los conocimientos generales del Rb, su diagnóstico y tratamiento. Se realizó una revisión de los avances más recientes en esta enfermedad publicados en PubMed y se resumieron los hallazgos más importantes.La sospecha oportuna y la referencia adecuada de pacientes permiten que el tratamiento conservador del Rb sea curativo. En países en vías de desarrollo, el tratamiento primario es el salvamento ocular y la preservación de la visión. Las opciones de quimioterapia intraarterial o intravítrea permiten ofrecer opciones terapéuticas en estos pacientes.Los avances en el tratamiento del Rb están generalmente limitados a países industrializados. Las implicaciones de los hallazgos de esta revisión serán discutidas en la segunda parte, la cual será un análisis de la situación de los programas hospitalarios del Rb en México, incluyendo la revisión de los datos demográficos disponibles de los centros de referencia más importantes.

Persons with disabilities, cancer screening and related factors / Pessoas com deficiência, exames preventivos de câncer e fatores relacionados

The scope of this article is to describe persons with disabilities (PwD) being subjected to cancer screening and the relationship between some social variables and inequalities in performing these tests. A cross-sectional study of cancer screening among PwD was conducted in 2007 with 333 participants interviewed in residence in 4 cities of São Paulo. Variables in the practice of cancer screening, disabilities, gender, age, income of main family breadwinner, ethnicity, use of health services, assistance required, private health insurance, and coverage by the family health program were studied. Frequencies, χ²-test, trend χ² percentages and the Odds Ratios (OR) were used for data analysis. 44% of PwD attended at least one cancer screening at the appropriate time. Persons with visual disabilities and with hearing disabilities were subjected to more screening examinations than those with mobility disabilities and women were attended in screening exams more than men. Persons between the ages of 21 and 60 reported cancer screening more frequently than those between 80 and 97 years of age. The outcomes indicate that PwD have different attitudes toward cancer screening according to the type of disability, gender, and age, which were the variables that directly influenced cancer screening exams.

O objetivo deste artigo é descrever a realização de exames preventivos de câncer entre pessoas com deficiências (PD) e a relação entre algumas variáveis sociais e as desigualdades na realização dos exames. Estudo transversal sobre exames preventivos de câncer entre PD. Foram entrevistadas em domicílio 333 pessoas em quatro cidades de São Paulo, em 2007. Estudou-se variáveis relacionadas aos exames preventivos, deficiências, gênero, idade, renda do chefe da família, etnia, uso de serviços de saúde, assistência necessária, plano privado de saúde e cobertura pela Estratégia de Saúde da Família. Para a análise usou-se frequências, porcentagens, teste de χ², χ² de tendência e Odds Ratio (OR). Dos entrevistados, 44% realizou pelo menos um exame preventivo na época correta. Pessoas com deficiência visual e com deficiência auditiva fizeram mais exames do que aqueles com deficiência física. Mulheres fizeram mais exames que os homens e pessoas com idade entre 21 e 60 anos relataram maior frequência de exames que aquelas entre 80 e 97 anos. Os achados indicam que as PD tiveram diferentes padrões de realização de exames preventivos segundo o tipo de deficiência, gênero e idade, sendo estas as variáveis de influência direta na realização de exames preventivos de câncer.

Nanochips y nanosensores para eldiagnóstico temprano de cáncer oral: una revisión / Nanochips and nanosensors for harly oral cancer diagnosis: a review

Antecedentes: El cáncer oral es una de las enfermedades más agresivas y con mayor probabilidadde metástasis; en estadios iniciales es generalmente indetectable y de baja consulta,por lo que se dificulta realizar un tratamiento conservador. Existen diversas técnicas delaboratorio con base en microscopía (como inmunofluorescencia), inmunohistoquímica yotras que facilitan el diagnóstico temprano de la enfermedad. Adicionalmente, los avancesen nanomedicina brindan nuevas herramientas de detección a partir de cambios moleculares(biomarcadores) que presentan las células en proceso de malignización. Objetivo:Describir las características clínicas y moleculares de lesiones premalignas y cáncer oral ylos métodos de diagnóstico usando nanotecnología (nanochips, nanosensores, etc.), comoun método eficaz para la detección temprana del cáncer. Método: Se buscó literatura sobrenanotecnología y diagnóstico de cáncer oral en bases de datos como Science Direct yPubMed; la información de cada uno de los artículos se sintetizó con resúmenes individualespor los investigadores, se agrupó y redactó. Resultados: Se seleccionaron 46 artículos que,de acuerdo con su contenido, se agruparon según su temática principal; toda la informaciónse relacionó en una tabla por subtemas en Excel® 2007. Conclusiones: La literatura revisadasugiere que las herramientas nanotecnológicas pueden ser una alternativa útil y rápida,aunque por el momento costosa, para la detección puntual de biomarcadores presentes enestadios iniciales del cáncer oral. Cabe mencionar que su aplicación clínica en países comoColombia es limitada por factores como insuficientes recursos asignados a la investigacióny poca investigación en esta temática...

Background: Oral cancer is one of the most aggressive diseases with a high likelihood ofmetastases; it is undetectable during initial stages with low medical visits, making it difficultto provide conservative treatment. Several techniques such as microscopy (using for instanceimmunofluorescence) and immunohistochemistry make early diagnosis and cancerdetection easier. In addition, advances in nanomedicine offer new tools to detect molecularchanges (biological markers/biomarkers) in cells during a malignant process. Purpose:Describe molecular and clinic characteristics of premalignant lesions and oral cancer, aswell as techniques involving nanotechnology (lab-on-a-chip devices, nanosensors, etc.) aseffective methods for early cancer diagnosis. Methods: A literature review on nanotechnologyand oral cancer using databases such as Science Direct and PubMed was carried out;data from each article were summarized, grouped, and described. Results: 46 articles wereselected and grouped according to their main topic; data were compiled in an Excel 2007spreadsheet. Conclusions: The literature reviewed suggests that tools using nanotechnologycan be a useful and a quick alternative, though expensive, to detect specific biomarkers thatare present in early stages of oral cancer. It is important to point out that their clinical usein countries like Colombia is still limited by factors like the lack of resources allocated forresearch and the little research carried out on this subject...

Citología de cuello uterino e impeditividad eléctrica en la detección temprana del cáncer cervical / Cervical Cytology and Electrical Impedivity in the Early Detection of the Cervical Cancer

Se reportan los resultados de un estudio piloto de las propiedades eléctricas del tejido epitelial de cuello uterino por medio de espectroscopia de impeditividad eléctrica, con el propósito de estudiar la detección temprana de la neoplasia intraepitelial con éste método. Para ello, se midieron 636 espectros de impeditividad eléctrica en 53 pacientes de la Liga Santandereana de Lucha Contra el Cáncer, los cuales fueron comparados con las citologías cervicales. Los datos experimentales fueron ajustados al modelo de Cole-Cole con una herramienta computacional basada en algoritmos genéticos. Los resultados del estudio realizado sugieren una sensibilidad y especificidad superiores al 70%. Salud UIS 2012; 44 (2):15-19.

Are reported the results of a study about the properties of cervical epitelial tissue using electrical impeditivity spectroscopy, with the objective of studying the early detection of intraepithelial neoplasia, with this metled. 636 impedivity spectrums from 53 patients at Liga Santandereana de Lucha contra el cancer were measured and compared with cervical cytology. Experimental data were felted to the Cole-Cole model, using a computational tool based in genetic algorithms. The results of the study suggest a sensibility and specificity above 70%. Salud UIS 2012; 44 (2):15-19.

Prostate Cancer Detection by Transrectal Ultrasound Guided Prostate Biopsy: Urology versus Radiology at a Single Academic Institution / 대한남성과학회지

PURPOSE: Many centers rely on radiologists to detect prostate cancer by transrectal ultrasound guided prostate biopsy. In this study we evaluated transrectal ultrasound guided prostate biopsy by radiologist or urologist, and compared prostate cancer detection rate, pathologic results and pain scrore. MATERIAL AND METHODS: In all, 259 consecutive patients had transrectal ultrasound guided prostate biopsy by one radiologist (group 1) and one urologist (group 2). The indication for prostate biopsies were a raised or rising prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE). All data were collected prospectively. RESULTS: Both group showed comparable demographic data in age, PSA, prostate volume. But pain score showed higher in urologist group (p10 ng/ml. Both groups had similar Gleason score (6.8+/-0.7 vs 6.7+/-0.8) and number of cancer cores (3.0+/-1.7 vs 3.9+/-2.3). Group 1 showed significantly low visual analogue pain scale compared with Group 2 (2.9+/-1.9 vs 4.0+/-2.1)(p<0.05). CONCLUSION: Transrectal ultrasound guided prostate biopsy showed equally reliable datas whether performed by radiologist or urologist. The urologist can effectively perform transrectal ultrasound guided prostate biopsy like radiologist in detecting prostate cancer. Also we recommend to perform anesthesia to relieve pain before prostate biopsy and furthermore future studies with more patients with more datas are needed.

Prostate Cancer Detection Rate According to Prostate Volume and Age With PSA Levels of above 4.0ng/ml / 대한남성과학회지

PURPOSE: We retrospectively investigated the changes of prostate cancer detection rate according to patients prostate volume, age with prostate-specific antigen (PSA) levels of above 4.0ng/ml. MATERIAL AND METHODS: Data were collected from 663 patients who underwent 10 core prostate biopsy for elevated PSA above 4.0ng/ml. The biopsy-proven cancer patient group was compared to the non-cancer patient group according to age, PSA, prostate volume and PSAD. Prostate cancer detection rate was calculated according to prostate volume (less than 40 vs 40 or more 40ml) and age (less than 60, 60-69, 70-79, 80 or more years old). Also we compared prostate cancer detection rate according to PSA levels (4-10 vs 10-20ng/ml). RESULTS: Among the 663 patients who underwent prostate biopsy, prostate cancer was detected in 134 patients (20.2%). There were no stastically difference in mean age, mean prostate volume, and mean PSAD except mean PSA (13.9 vs 11.9ng/ml) between cancer and non-cancer groups. The cancer detection rate in small prostate was significantly higher than large prostate (23.5% vs 16.0%). The cancer detection rate was significantly increased with age: from 14.5% for below 60 year-old patients to 30.3% for the 80 or more year-old patients. There was no significant difference in cancer detection rate between the two PSA groups (19.0 vs 20.5%). CONCLUSION: Prostate cancer detection rate was higher in old patients and patients with small prostate volume. The older age group and the patients with small prostate volume was considered as the important factors to decide whether biopsy of prostate is needed.

A look at utilization and cancer detection yield of mammography

BACKGROUND: In the Philippines, mammography is frequently requested in the evaluation of patients with breast cancer concern. OBJECTIVES: The general objective was to take a look at the practice of requesting for a mammography in a health care institution and its outcome in terms of cancer detection in patients with non- palpable breast masses. METHODS: A retrospective review of past records from 1994 to 2001 was accomplished. RESULTS: A total of 7,323 mammog-raphies. 192 (3 percent) were done in the 20-29 age group; 966 (13 percent) in 30-39 age group; 2708 (37 percent) in 40-49 age group, 2410 (33 percent) in 50-59 age group and the remaining 1047 (14 percent) in those older than 60 years old. The top three physicians requesting for mammography were obstetrician-gynecologists, 2337 (32 percent); general surgeons, 1348 (18 percent) and internists and family medicine specialists, 806 (10 percent). Normal findings were reported in 4449 (61 percent); benign in 2721 (37 percent), suspicious for cancer without a clinically palpable mass in 99 (1.35 percent) and suspicious for cancer with a palpable breast mass in 52 patients (0.74 percent). A total of 50 patients underwent needle localization biopsy of which 35 had fibrocystic changes (70 percent), 10 had cancer (20 percent) and 5 with indefinite results. CONCLUSION: The overall cancer detection yield for mammography in those without a palpable breast mass, 7271 (7323-52) persons, was extrapolated to be 0.28 percent (20/7271). The authors deemed the information obtained in this study would be useful to the public, health care administrators and health care providers in reviewing the indication and cost-effectiveness of mammography.

Technical refinements of transrectal ultrasound-guided prostate biopsy in prostate cancer detection

Rationale: In the Philippine setting, prostate cancer detection using sextant biopsy techniques yielded result ranging from 6-10 percent. However, with the introduction of the 12 core systematic biopsy technique, the cancer detection increased to 23 percent. The yield is still inferior compared to foreign counterpart and a deeper reassessment of the biopsy technique may prove otherwiseObjective: This study aims to evaluate cancer detection using a technical refinement wherein an ultrasound machine is used to visualize the prostate gland both in sagittal and longitudinal views, directing the biopsies more laterally to better sample regions of the peripheral zone using the marker lineMethods: This is a prospective cohort study of 68 consecutive males who underwent prostate biopsy from two tertiary hospitals performed by one consultant from January to September 2004. The indications for prostate biopsy included an elevation of serum PSA and/or an abnormal digital rectal examination. However, due to higher likelihood of prostate cancer in men with higher PSA, patients with PSA above 20 ng/ml were excluded from this study. The ultrasound machine used in Group A was ACUSON while that in group B used Bruel Kjaer 5001. All patients underwent a systematic 12 core biopsy techniqueResults: A total of 68 male patients with a mean age of 66.11 +/- 8.09 years, who underwent transrectal ultrasound guided prostate biopsy using the twelve core protocol from January to September 2004 were included. Twenty-eight (28) patients were included in group A and 40 were in group B. The pre-biopsy PSA level taken showed a mean of 9.55 +/- 3.03. The mean prostate gland volume on transrectal ultrasound was 39.67 +/- 13.6 and 39.67 +/- 16.9 for group A and B, respectively. The overall cancer detection rate from the total study population was 41.3 percent. Detection rate of the two populations were compared using the Wilcoxon Signed Rank Test and the Mc Nemars Test. The detection rate for group A was 21 percent while the detection rate for group B using the technical modification was 50 percent. There was a significant difference in cancer detection between the two populations at z= 2.53, p=0.01 using Wilcoxon Signed Rank Test and at p=0.02 in Mc Nemars test. Reliability analysis was also done to determine differences in the detection rates of the tests done in the two different institutions. Friedmans chi square, x2 was 14.8 at p=0.002, which means that the detection rates between the two institution was significantly differentConclusion: The prostate biopsy technique of using biplanar transrectal probe that allows confirmation of the needle tract in the transverse view before doing the biopsy in the sagittal view of the prostate increased the yield of prostate cancer detection to 50 percent. The conventional 12 core biopsy technique still maintained a 21 percent detection, which is not different from previous reports from the same institution. (Author)